Midgard
C

셀트리온 Celltrion

Incheon, South Korea celltrion.com From their website, Nov 2026

  • GMP

Work here? Claim this listing

About

Celltrion develops, manufactures, markets, and sells biopharmaceuticals, biosimilars, small molecules, and novel therapeutics. It operates from Incheon, South Korea, with production facilities in Songdo and a plant in Branchburg, New Jersey, and serves global markets including North America, Europe, Asia, and South America.

Services

  • Antibody biopharmaceutical R&D

    Develops biopharmaceuticals including novel antibody discoveries, biosimilar development, novel therapeutics development, and platform technology development.

  • Small molecule R&D

    Develops new chemical entities, generic products, chemical IMDs, and platform technologies for small molecules.

  • Candidate antibody screening

    Screens candidate antibodies and develops target product profiles.

  • Cell line development

    Develops high-expression cell lines and secures intellectual property rights to source technologies.

    Cell line development

  • Process development

    Develops cell culture and purification processes and optimizes processes for commercial manufacturing.

  • Analytical method development

    Develops analytical methods based on A-QbD and studies physicochemical and biological properties, similarity, stability, mechanism of action, and bioanalytical methods.

  • Formulation development

    Carries out preliminary formulation development, formulation characterization studies, delivery device development, and primary container closer system studies.

  • Pharmacology and toxicology

    Conducts pharmacokinetics, pharmacodynamics, and toxicology studies.

3 more services
  • Biopharmaceutical manufacturing
  • Contract manufacturing
  • Distribution

Capabilities

Assays and studies
  • Antibodies
  • Small molecules
  • Process development
  • Analytical development
  • Toxicology
  • PK/PD
8 more
  • Bioanalysis
  • Analytical method development
  • Physicochemical characterization
  • Biological characterization
  • Similarity study
  • Stability study
  • Mechanism of action study
  • Bioanalytical method development
Scale and capacity
  • Songdo campus production capacity of 250,000L
  • Branchburg plant biopharmaceutical production capacity of 66,000L
  • Songdo Plant 1: 100,000L
  • Songdo Plant 2: 90,000L
  • Songdo Plant 3: 60,000L
  • Branchburg Plant: 11,000L x 6 lines
  • PFS filling capacity up to 20.8 million syringes per year
Therapeutic areas
  • Immunology
  • Oncology
  • Haematology
  • Ophthalmology
  • Endocrinology
  • Chronic spontaneous urticaria
5 more
  • Allergic asthma
  • Chronic rhinosinusitis with nasal polyps
  • Inflammatory bowel disease
  • Metastatic colorectal cancer
  • Breast cancer

Instruments and platforms

  • Prefilled syringe (PFS) production facility

Modalities and species

Modalities
  • Small molecule
  • Antibody
  • ADC
  • Biosimilar
Species and models
  • Animal cell culture facilities
  • Cell lines

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GMPSelf-reported

Details

Type
CRDMO
Founded
2002
Based in
Incheon, South Korea
Sites
  • Songdo, South Korea
  • Cheongju, South Korea
Serves
North America, Europe, Asia, South America, global

Public records

FDA drug establishment registration
3005241015 · ANALYSIS; API MANUFACTURE; LABEL; MANUFACTURE; PACK source
Wikidata
Q30260343 source

Similar labs